KINETIC-PROPERTIES OF HIV-1 PROTEASE PRODUCED BY TOTAL CHEMICAL SYNTHESIS WITH CYSTEINE RESIDUES REPLACED BY ISOSTERIC L-ALPHA-AMINO-N-BUTYRIC ACID

被引:18
作者
BERGMAN, DA
ALEWOOD, D
ALEWOOD, PF
ANDREWS, JL
BRINKWORTH, RI
ENGLEBRETSEN, DR
KENT, SBH
机构
[1] UNIV QUEENSLAND, CTR DRUG DESIGN & DEV, BRISBANE, QLD 4072, AUSTRALIA
[2] SCRIPPS RES INST, LA JOLLA, CA 92037 USA
来源
LETTERS IN PEPTIDE SCIENCE | 1995年 / 2卷 / 02期
关键词
SYNTHETIC ENZYME; ASPARTIC ENDOPEPTIDASE; AIDS; ENZYME KINETICS;
D O I
10.1007/BF00128504
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human immunodeficiency virus-1 protease, produced by total chemical synthesis with the cysteine residues replaced by L-alpha-amino-n-butyric acid ([Aba(67,95)] HIV-1 PR), has been used extensively for the X-ray crystallographic structural analysis of the enzyme and its complexes utilized in drug design. Here we report kinetic studies on the synthetic enzyme. The pH optimum is 5.5 at ionic strengths of 0.1 and 1.0. The acid pH optimum is due to a decrease in binding affinity at higher pH values rather than to a reduction in catalytic efficiency. Activity is markedly increased by high ionic strength, although the major effect is on K-m and not k(cat). The effect of pH and ionic strength on the kinetic constants determined for substrates and inhibitors is demonstrated and attention is drawn to the need for assay conditions to be explicitly reported in studies on inhibitor activity. The effect of a number of inhibitors has been measured against the synthetic enzyme and a recombinant HIV-1 PR. This work shows that [Aba(67,95)] HIV-1 PR has full enzymatic activity and normal kinetic properties.
引用
收藏
页码:99 / 107
页数:9
相关论文
共 51 条
  • [1] SOLID-PHASE SYNTHESIS OF HYDROXYETHYLAMINE PEPTIDE-BOND ISOSTERES - SYNTHESIS OF THE POTENT-HIV-1 PROTEASE INHIBITOR JG365
    ALEWOOD, PF
    BRINKWORTH, RI
    DANCER, RJ
    GARNHAM, B
    JONES, A
    KENT, SBH
    [J]. TETRAHEDRON LETTERS, 1992, 33 (07) : 977 - 980
  • [2] BILLICH S, 1988, J BIOL CHEM, V263, P17905
  • [3] DARKE PL, 1989, J BIOL CHEM, V264, P2307
  • [4] DEBOUCK C, 1989, VIRAL PROTEINASES TA, P127
  • [5] STRUCTURE-BASED DESIGN OF NONPEPTIDE INHIBITORS SPECIFIC FOR THE HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE
    DESJARLAIS, RL
    SEIBEL, GL
    KUNTZ, ID
    FURTH, PS
    ALVAREZ, JC
    DEMONTELLANO, PRO
    DECAMP, DL
    BABE, LM
    CRAIK, CS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (17) : 6644 - 6648
  • [6] THE DETERMINATION OF ENZYME INHIBITOR CONSTANTS
    DIXON, M
    [J]. BIOCHEMICAL JOURNAL, 1953, 55 (01) : 170 - 171
  • [8] ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405
  • [9] ENGLEBRETSEN D, 1995, IN PRESS TETRAHEDRON
  • [10] DESIGN, ACTIVITY, AND 2.8 A CRYSTAL-STRUCTURE OF A C2 SYMMETRICAL INHIBITOR COMPLEXED TO HIV-1 PROTEASE
    ERICKSON, J
    NEIDHART, DJ
    VANDRIE, J
    KEMPF, DJ
    WANG, XC
    NORBECK, DW
    PLATTNER, JJ
    RITTENHOUSE, JW
    TURON, M
    WIDEBURG, N
    KOHLBRENNER, WE
    SIMMER, R
    HELFRICH, R
    PAUL, DA
    KNIGGE, M
    [J]. SCIENCE, 1990, 249 (4968) : 527 - 533